Owen Joseph S, Khatib Sammy, Morin Daniel P
Division of Cardiology, Ochsner Clinic Foundation, New Orleans, LA.
Ochsner J. 2009 Winter;9(4):248-56.
Systolic heart failure is a major problem for Americans today, with 550,000 new cases diagnosed per year, and ultimately contributes to 287,000 deaths annually. While pharmacologic therapy has drastically improved outcomes in patients with systolic heart failure, hospitalizations from systolic heart failure continue to increase and remain a major cost burden. In response to this unmet need, recent years have seen dramatic improvements in device-based therapy targeting one cause of systolic dysfunction: dyssynchronous ventricular contraction. Cardiac resynchronization therapy aims to restore mechanical synchrony by electrically activating the heart in a synchronized manner. This review summarizes the rationale for cardiac resynchronization therapy, evidence for its use, current guidelines, and ongoing and future directions for research.
收缩性心力衰竭是当今美国人面临的一个主要问题，每年有55万新病例被诊断出来，最终每年导致28.7万人死亡。虽然药物治疗已极大地改善了收缩性心力衰竭患者的治疗效果，但因收缩性心力衰竭住院的人数仍在不断增加，且仍然是一个主要的成本负担。为了满足这一未得到满足的需求，近年来，针对收缩功能障碍的一个原因——心室收缩不同步，基于设备的治疗取得了显著进展。心脏再同步治疗旨在通过以同步方式电激活心脏来恢复机械同步性。本综述总结了心脏再同步治疗的基本原理、其使用的证据、当前指南以及正在进行的和未来的研究方向。
